- Home
- LEGH vs OLMA Comparison
LEGH vs OLMA Comparison
Compare LEGH & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- OLMA
- Stock Information
- Founded
- LEGH 2005
- OLMA 2006
- Country
- LEGH United States
- OLMA United States
- Employees
- LEGH N/A
- OLMA N/A
- Industry
- LEGH Homebuilding
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- LEGH Consumer Discretionary
- OLMA Health Care
- Exchange
- LEGH Nasdaq
- OLMA Nasdaq
- Market Cap
- LEGH 646.4M
- OLMA 560.7M
- IPO Year
- LEGH 2018
- OLMA 2020
- Fundamental
- Price
- LEGH $24.90
- OLMA $11.10
- Analyst Decision
- LEGH Strong Buy
- OLMA Strong Buy
- Analyst Count
- LEGH 1
- OLMA 5
- Target Price
- LEGH $29.00
- OLMA $24.00
- AVG Volume (30 Days)
- LEGH 68.6K
- OLMA 1.2M
- Earning Date
- LEGH 11-11-2025
- OLMA 11-11-2025
- Dividend Yield
- LEGH N/A
- OLMA N/A
- EPS Growth
- LEGH 2.38
- OLMA N/A
- EPS
- LEGH 2.23
- OLMA N/A
- Revenue
- LEGH $184,284,000.00
- OLMA N/A
- Revenue This Year
- LEGH $1.51
- OLMA N/A
- Revenue Next Year
- LEGH $7.92
- OLMA N/A
- P/E Ratio
- LEGH $11.25
- OLMA N/A
- Revenue Growth
- LEGH 8.79
- OLMA N/A
- 52 Week Low
- LEGH $21.58
- OLMA $2.86
- 52 Week High
- LEGH $29.45
- OLMA $13.51
- Technical
- Relative Strength Index (RSI)
- LEGH 30.29
- OLMA 77.80
- Support Level
- LEGH $26.90
- OLMA $8.01
- Resistance Level
- LEGH $27.59
- OLMA $11.50
- Average True Range (ATR)
- LEGH 0.88
- OLMA 0.78
- MACD
- LEGH -0.26
- OLMA 0.22
- Stochastic Oscillator
- LEGH 4.43
- OLMA 88.57
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.